Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Neomycin Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults

NCT00350337
View directory record Official record
Conditions
Dengue
Interventions
Pre-transfection F17, Post-transfection F17, Post-transfection F19, Placebo
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Sep 6, 2026, 2:13 AM EDT
Completed Not applicable Interventional

Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine

NCT00000635
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Trifluridine, Bacitracin zinc/Polymyxin B sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 6, 2026, 2:13 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease

NCT01731236
View directory record Official record
Conditions
Dietary Modification
Interventions
Carnitine, Choline, Antibiotics, Choline and Aspirin, Carnitine and Aspirin
Dietary Supplement · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 6, 2026, 2:13 AM EDT
Recruiting Phase 2 Interventional

Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients

NCT05695261
View directory record Official record
Conditions
Allergy, Peanut, Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Food Allergy, Food Allergy Peanut
Interventions
Microbial Transplantation Therapy, Antibiotic, Placebo (in place of MTT), Placebo (in place of antibiotics), Oral Immunotherapy (OIT)
Biological · Drug · Other
Lead sponsor
Rima Rachid
Other
Eligibility
12 Years to 17 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 6, 2026, 2:13 AM EDT
Terminated Early Phase 1 Interventional

Patients Response to Early Switch To Oral:Osteomyelitis Study

NCT02099240
View directory record Official record
Conditions
Osteomyelitis
Interventions
oral antibiotics, intravenous antibiotics
Drug · Procedure
Lead sponsor
Julio Ramirez
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 6, 2026, 2:13 AM EDT
Completed Phase 1 Interventional

Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL

NCT00058617
View directory record Official record
Conditions
Epstein-Barr Virus-Related Hodgkin Lymphoma, Epstein-Barr Virus-Related Non-Hodgkin Lymphoma, EBV Positive Plasma Cell Neoplasm
Interventions
Injection of EBV Specific CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Sep 6, 2026, 2:13 AM EDT
Completed Not applicable Interventional

Precision Dosing of Alemtuzumab

NCT03302754
View directory record Official record
Conditions
Allogeneic Hematopoietic Cell Transplantation
Interventions
Alemtuzumab
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Weeks to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 6, 2026, 2:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Topical Antibacterial Agents for Prevention of COVID-19

NCT05449392
View directory record Official record
Conditions
COVID-19, SARS-CoV2 Infection
Interventions
Neosporin, Vaseline
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 6, 2026, 2:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Neo-Synalar Modified 48 Hour Patch Test

NCT02168478
View directory record Official record
Conditions
Allergy
Interventions
Neo-Synalar Cream, Sodium Lauryl Sulfate Aqueous Solution (0.40%), Saline
Drug · Other
Lead sponsor
Noah Rosenberg, MD
Industry
Eligibility
18 Years to 79 Years
Enrollment
206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Sep 6, 2026, 2:13 AM EDT
Recruiting Phase 2 Interventional

Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata

NCT06747611
View directory record Official record
Conditions
Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions
Vancomycin, Neomycin and MTT capsules, Placebo capsules
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 6, 2026, 2:13 AM EDT
Completed Phase 1 Interventional Results available

LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma

NCT00062868
View directory record Official record
Conditions
Hodgkin Disease, Non Hodgkin Lymphoma, Lymphoepithelioma, Leiomyosarcoma
Interventions
LMP1/2 CTLs (ALCI - Group A), LMP1/2 CTLs (ALCI - Group B), LMP1/2 CTLs (ALCI - Group C), LMP2 CTLs (ALSCER - Group A), LMP2 CTLs (ALSCER - Group B), LMP2 CTLs (ALSCER - Group C), LMP1/2 CTLs (ALCI - Expansion - Group A), LMP1/2 CTLs (ALCI - Expansion Group B), LMP1/2 CTLs (ALCI - Expansion Group C)
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Sep 6, 2026, 2:13 AM EDT
Recruiting Phase 1 Interventional

Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure

NCT07490054
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
MTP-101-C encapsulated Microbiota, Vancomycin, Neomycin
Biological · Drug
Lead sponsor
Melana Yuzefpolskaya, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 6, 2026, 2:13 AM EDT
Completed Not applicable Interventional Results available

Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome

NCT00945334
View directory record Official record
Conditions
Constipation-predominant Irritable Bowel Syndrome
Interventions
Neomycin, Placebo, Rifaximin
Drug
Lead sponsor
Mark Pimentel, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Los Angeles, California • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 9, 2015 · Synced Sep 6, 2026, 2:13 AM EDT
Recruiting Phase 4 Interventional

Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population

NCT05157113
View directory record Official record
Conditions
Cataract, Surgery, Compliance, Patient, Compliance, Medication, Satisfaction, Patient
Interventions
Dropless Regimen, Standard Regimen
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Sep 6, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

NCT03476317
View directory record Official record
Conditions
Crohn Disease
Interventions
Vancomycin, Neomycin, Ciprofloxacin, Polyethylene Glycol 3350, Fluconazole
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Sep 6, 2026, 2:13 AM EDT
Completed Early Phase 1 Interventional Results available

Role of Methane in Glycemic Control

NCT01638429
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
Neomycin, Rifaximin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Sep 6, 2026, 2:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Analysis of MicroBial Metabolites After Eating Refined Food

NCT04308473
View directory record Official record
Conditions
Dietary Habits
Interventions
Ultra-processed Food Meal, Whole Food Meal
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 6, 2026, 2:13 AM EDT
Completed Phase 1 Interventional

Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma

NCT02792036
View directory record Official record
Conditions
Retinoblastoma
Interventions
Carboplatin, Maxitrol®, Focal Therapy, Plaque Radiotherapy
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 6, 2026, 2:13 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Dropless Pars Plana Vitrectomy Study

NCT05331664
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment
Interventions
Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin, Prednisolone 1%, Atropine 1%
Procedure · Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 6, 2026, 2:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics

NCT02154061
View directory record Official record
Conditions
Influenza
Interventions
IIV Flu Vaccine, Metronidazole, Neomycin, Vancomycin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 40 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Sep 6, 2026, 2:13 AM EDT
Active, not recruiting Phase 2 Interventional

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

NCT04729322
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Biopsy, Fecal Microbiota Transplantation, Fecal Microbiota Transplantation Capsule, Metronidazole, Neomycin, Nivolumab, Pembrolizumab, Questionnaire Administration, Vancomycin
Procedure · Drug · Biological + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 6, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

NCT02765256
View directory record Official record
Conditions
Crohn's Disease
Interventions
Fluconazole, Vancomycin, Neomycin, Ciprofloxacin, Polyethylene Glycol 3350, Promethazine, Fluconazole placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Sep 6, 2026, 2:13 AM EDT
Terminated Phase 1 Interventional

Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease

NCT00058773
View directory record Official record
Conditions
Hodgkin Disease, Non-Hodgkins Lymphoma
Interventions
Infusion of EBV Specific Cytotoxic T-Lymphocytes
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Sep 6, 2026, 2:13 AM EDT
Completed Phase 1 Interventional

Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative Colitis

NCT03006809
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Fecal Microbiota Transplantation (FMT), OpenBiome, pretreatment antibiotics
Biological · Other
Lead sponsor
Najwa Elnachef
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 6, 2026, 2:13 AM EDT